Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

U.S. Centers for Medicare and Medicaid Services (CMS)

Trump Names Healthcare Consultant Seema Verma to Head Centers for Medicare and Medicaid Services

Seema Verma

Seema Verma

Washington, DC, November 29, 2016 — Politico today reports that President-elect Donald Trump on Tuesday morning picked the founder and CEO of a health policy consulting firm, Seema Verma, to serve as Administrator of the Centers for Medicare and Medicaid Services.

“I am pleased to nominate Seema Verma to serve as Administrator of the Centers for Medicare and Medicaid Services,” said President-elect Trump in a statement.

Trump continued, “She has decades of experience advising on Medicare and Medicaid policy and helping states navigate our complicated systems.  Together, Chairman Price and Seema Verma are the dream team that will transform our healthcare system for the benefit of all Americans.” Continue reading

Pharmalot: Senate Republicans Urge Obama to Withdraw Medicare Part B Experiment

STAT PharmalotBoston, MA, May 2, 2016 ― Pharmalot reporter-blogger Ed Silverman reports on STAT News that one month after the Obama administration unveiled an experiment to revamp the Medicare Part B program, more than a dozen Republican Senators are urging that it be withdrawn.

At the same time, House Republicans and Democrats are circulating letters among themselves that express varying degrees of concern with the program.

In a letter sent on Friday to the U.S. Centers for Medicare and Medicaid Services, the Senators charged that the program would “severely disrupt care for vulnerable beneficiaries with cancer” and other serious medical conditions.

The Senators also complained that CMS failed to undertake a fully transparent process to assemble its program. Continue reading